Compare Dropbox Inc (DBX) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Heron Therapeutics Inc — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.19B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Dropbox Inc is far larger — about 97.1× Heron Therapeutics Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Heron Therapeutics Inc for 35 Days on average.
| DBX | HRTX | |
|---|---|---|
Market Cap | $7.19B | $74.04M |
Volume | 2,804,312 | 3,668,095 |
Sector | Technology | Health |
52-Week High | $37.74 | $1.49 |
52-Week Low | $22.06 | $0.27 |
Typical Hold Time | 97 Days | 35 Days |
Enterprise Value | $10.05B | $180.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $34.14, up 1.22% on the day, with a bearish technical signal and mixed analyst ratings. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $0.728. Revenue remains stable around $2.5B annually, with a high gross margin of 79.72%, but net cash flow turned negative in 2025 due to significant financing outflows. Recent news highlights insider selling and a security breach affecting 5,000 accounts.
The outlook is cautious; while profitability is solid, stagnant revenue growth and high debt levels pose risks. The consensus price target of $26.83 suggests downside potential. Investor sentiment is divided, with technical indicators signaling bearish pressure. Key risks include competitive threats and execution challenges in a mature market.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
